RX-5902 Treatment of Subjects With Triple Negative Breast Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

18 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-08-31

Study Completion Date

2019-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this Phase 2 portion of the study is to use the dose and schedule of RX-5902 identified in the phase 1 to treat subjects with triple negative breast cancer.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Cabozantinib for Metastatic Triple Negative BrCa

NCT01738438

Breast Cancer

COMPLETED PHASE2

Intravenous RPR109881 in Male or Female Patients With Advanced Breast Cancer Who no Longer Respond to Anthracycline, Taxane and Capecitabine Treatment

NCT00087958

Breast Cancer

COMPLETED PHASE2

Patient-derived Xenograft (PDX) Modeling of Treatment Response for Triple Negative Breast Cancer

NCT02247037

Triple Negative Breast Cancer

COMPLETED

Tanespimycin in Treating Women With Refractory Locally Advanced or Metastatic Breast Cancer

NCT00096109

Recurrent Breast Cancer Stage IIIB Breast Cancer Stage IIIC Breast Cancer +1 more

TERMINATED PHASE2

A Phase II Study of Nivolumab in Combination With Cabozantinib for Metastatic Triple-negative Breast Cancer

NCT03316586

Breast Cancer

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In this dose-finding, open-label, single-agent study of RX-5902, subjects will be treated for up to 6 cycles of therapy. RX-5902 will be administered orally daily for 3 weeks followed by 1 week of rest in each cycle. All subjects will be followed for at least 30 days after the last dose of study agent for safety.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Solid Tumor Triple Negative Breast Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

RX-5902

RX-5902 will be taken daily for 4 weeks in each 4 week cycle. Subjects will be fasting for 8 hours before and food may be ingested approximately 3 hours after the dose has been administered.

Group Type EXPERIMENTAL

RX-5902

Intervention Type DRUG

escalating doses (mg)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

RX-5902

escalating doses (mg)

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Supinoxin™

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male and female who are 18 yrs or older
* Histologically confirmed triple negative breast cancer that are refractory, intolerant, or ineligible to receive approved standard therapies
* Measurable or evaluable disease per Response Evaluation Criteria in Solid Tumors (RECIST)
* Life expectancy of at least 3 months
* Able to swallow capsules
* Provide written informed consent

Exclusion Criteria

* Primary brain tumor or active brain metastasis
* Not recovered to less than or equal to Grade 1 toxicities (except Grade 2 alopecia or neuropathy) associated with previous cancer therapies
* Any other cancer treatments within 2 weeks of planned study treatment
* History of any medical or psychiatric condition or addictive disorder, or lab abnormality that in the opinion of the investigator, may increase risks or may interfere with study participation or interpretation of study results
* History of clinically significant GI bleed, intestinal obstruction, or GI perforation within 6 months of study dose
* Uncontrolled diabetes
* History of long QT syndrome or clinically significant cardiac arrhythmias (except stable atrial fibrillation)
* Myocardial infarction within 6 months of study dose
* Active infection requiring IV antibiotics within 2 weeks of study dose
* History of Hepatitis B, C, or HIV
* Use of potent inhibitor or inducer of CYP3A4/3A5 within 14 days of planned study treatment or expected requirement for use of such a drug during study
* Use of a potent inhibitor or inducer of drug transporters or conjugating enzymes within 14 days prior to planned study treatment or expected requirement for use of such a drug during study
* Receiving other investigational agents or not yet completed 30 days since completion of an investigational study
* Pregnant, planning a pregnancy, or breast feeding
* Male or female not willing to use adequate contraceptive precautions during the study period. Females must either be surgically sterile, post-menopausal for 12 months, or use a contraceptive approved by sponsor.
* Unwilling or unable to provide written informed consent, comply with study requirements, or be available for follow-up assessments

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No